1. Scrip
  2. >>Drug Pricing

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: CMS’s price reveal better than expected?; new diabetes risk data for Zepbound; can J&J’s lung cancer combo stand up to Tagrisso?; new recruits for BioMarin leadership; and Glenmark’s shifting revenues.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 23 August 2024, including: CMS’s price reveal better than expected?; new diabetes risk data for Zepbound; can J&J’s lung cancer combo stand up to Tagrisso?; new recruits for BioMarin Pharmaceutical Inc. leadership; and Glenmark Pharmaceuticals Limited’s shifting revenues.

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "CMS’s Big Drug Price Reveal Turns Out Better For Pharma Than Feared" - Scrip, 15 August, 2024.)

(Also see "Lilly Data Show Zepbound Reduces Type 2 Diabetes Risk Long Term" - Scrip, 20 August, 2024.)

(Also see "Can J&J’s Rybrevant/Lazcluze Combo Stand Up To Tagrisso?" - Scrip, 20 August, 2024.)

(Also see "BioMarin Recruits Amgen R&D’s Friberg, Roche Dealmaker Sabry To Leadership Team" - Scrip, 21 August, 2024.)

(Also see "Glenmark Chief On ‘Big Shift’ In Revenue By Region, Liraglutide India Outlook" - Scrip, 21 August, 2024.)

Citeline · Scrip’s Five Must-Know Things - 26 August 2024

Open Media

More from Drug Pricing

Mounjaro In India: Price Differential, Window Of Opportunity

 
• By Anju Ghangurde

Lilly’s Mounjaro arrives in India, with the 2.5mg vial priced at under $41 in a market that has over 100 million diabetics and increasing obesity rates. Will the product see sharp demand like in China, carving out a chunk of the pie ahead of the potential arrival of semaglutide generics and could there be concerns of ‘suitcase' exports?

Stelara Biosimilars Storm US Market With 85% Discounts Ahead Of Price Drop In Medicare

 
• By Cathy Kelly

The development could highlight the power of competitive market forces over government price controls or suggest Medicare price negotiation is enhancing competitive market forces.

Alnylam Joins Competitive ATTR-CM Market With Amvuttra Approval

 
• By Jessica Merrill

Amvuttra will target a substantially larger patient population with a new indication, but it is third to market behind Pfizer’s Vyndaqel and Bridge Bio’s Attruby and will cost more.

India Landscape For Rare Disease Therapies: Hope, Despair And Funding Hoops

 
• By Anju Ghangurde

Policy advances, measures to back local production and crowdfunding action for gene therapies like Zolgensma bring hope for rare disease patients in India. Gaps in financing, high prices and an ongoing court case, however, stunt efforts to ensure timely access.

More from Scrip

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.

Rhythm Anticipates Smooth Sailing For Setmelanotide After Phase III Success

 
• By Alaric DeArment

The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.

Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings

 
• By Mandy Jackson

There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.